Indivior Pharmaceuticals, Inc. filed a Form 8-K with the SEC on September 17, 2026, disclosing that its board of directors declared a special cash dividend of $8.13 per share, contingent on the closing of its proposed merger with Supernus Pharmaceuticals, Inc.
Key Highlights
- Special dividend amount: $8.13 per share of Indivior common stock, declared by the board of directors on September 16, 2026.
- Record date: Holders of record as of October 30, 2026 will be eligible to receive the Special Dividend.
- Payment contingency: The Special Dividend is conditioned upon and contingent on the closing of the merger with Supernus Pharmaceuticals, Inc.
- Anticipated payment date: Assuming the merger closes on or about November 2, 2026, payment to record holders is anticipated on or about November 6, 2026.
- Equity award holders: $8.13 per share underlying Indivior equity awards outstanding as of the record date is also payable, upon vesting, to holders of certain equity awards.
- Tax treatment: The company disclosed it expects at least a majority of the Special Dividend to exceed current and accumulated earnings and profits, with amounts treated first as return of capital and then as capital gain for U.S. holders.
- Supernus stockholder exclusion: Supernus stockholders will not be entitled to receive the Special Dividend with respect to any Indivior common stock received as merger consideration.
Indivior Board Declares Merger-Contingent Dividend Ahead of Supernus Transaction
According to the filing, Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), a Delaware corporation headquartered in North Chesterfield, Virginia, reported that its board of directors on September 16, 2026 declared a special cash dividend of $8.13 per share of common stock. The filing states this dividend applies both to holders of record of issued and outstanding Indivior common stock and to holders of certain Indivior equity awards outstanding as of the Special Dividend Record Date of October 30, 2026, with the award-holder payment made upon vesting.
The filing connects the Special Dividend to a previously disclosed merger agreement entered into on August 1, 2026, under which Artemis Merger Sub Inc., a wholly owned subsidiary of Indivior, will merge with and into Supernus Pharmaceuticals, Inc. Under the agreement, Supernus would continue as the surviving company and a wholly owned subsidiary of Indivior following the transaction. The filing states that payment of the Special Dividend is "subject to and contingent upon the closing of the Merger" and that the closing is expected to occur on or about November 2, 2026, subject to, among other conditions, approval by both Indivior and Supernus stockholders and satisfaction or waiver of all conditions under the merger agreement.
Regarding the tax implications, the company disclosed that it expects "at least a majority of the Special Dividend to exceed Indivior's current and accumulated earnings and profits, although no assurance can be made in this regard." The filing directs holders to the joint proxy statement/prospectus filed with the SEC on September 11, 2026, for additional information on U.S. federal income tax considerations. The filing also notes that this Form 8-K was filed as a written communication pursuant to Rule 425 under the Securities Act. All forward-looking statements in the filing are the company's own and subject to its cautionary language regarding risks and uncertainties.
What Was Disclosed
Indivior Pharmaceuticals disclosed a special cash dividend of $8.13 per share declared on September 16, 2026, tied to the closing of its planned merger with Supernus Pharmaceuticals, with a record date of October 30, 2026, and an anticipated payment date on or about November 6, 2026.



Please wait processing your request...